Having Good Insurance can be Dangerous to Your Life and Your Wallet

Posted by

HealthTree

Vitamin D Levels Impact Myeloma Patient Outcomes After Transplant

Posted by

HealthTree

Which Myeloma Patients Have the Best Outcomes? New Study Shows Key Findings.

Posted by

HealthTree

Belantamab Mafodotin Receives FDA Approval for Relapsed Multiple Myeloma

Posted by

HealthTree

Belantamab Mafodotin Teams with SpringWorks Drug to Increase BCMA Expression in Early Myeloma Trial

Posted by

HealthTree

Six Steps for Newly Diagnosed Multiple Myeloma Patients

Posted by

HealthTree

Fenghuang “Frank” Zhan, M.D., Ph.D., Awarded Nearly $3.14 Million to Study Myeloma Genetics and Drug Resistance

Posted by

HealthTree

Conquer Magazine: How Real-World Evidence Has the Potential to Shape Real-World Outcomes in Multiple Myeloma

Posted by

HealthTree

Reflections on Ten Years With a Myeloma Diagnosis

Posted by

HealthTree

Understanding Disability and Social Security Benefits: Which Is Best for You?

Posted by

HealthTree

How Long Does COVID-19 Immunity Last?

Posted by

HealthTree

High Risk Myeloma and the Benefit of Tandem Transplants with Long-Term Revlimid Maintenance

Posted by

HealthTree

HealthTree Research: The Intersection of Psoriasis and Multiple Myeloma

Posted by

HealthTree

CelMoDs: Not Just Another Immmuno-modulatory Drug

Posted by

HealthTree

Another Bi-Specific Antibody for Multiple Myeloma Treatment

Posted by

HealthTree

The Power of Our Cancer Stories

Posted by

HealthTree

Good News: Long Term Follow Up of Revlimid/Velcade/Dex Use

Posted by

HealthTree

HealthTree University: Multiple Myeloma Basics Part 1 (3 of 3)

Posted by

HealthTree